Lumenis OptiLight wins the 2022 MedTech Breakthrough Award for Best New Technology Solution for Ophthalmology

For the third year in a row, Lumenis has been recognized for excellent medical technology and companies

Yokneam Illit, Israel 5/25/2022 –

For the third year in a row, Lumenis has been recognized for excellent medical technology and companies

Lumenis Be announced. , the leading manufacturer of energy-based medical devices for beauty and eye care applications, today announced that OptiLight was awarded the highly coveted MedTech Breakthrough Award in the “Best New Technology Solution for Ophthalmology” category. This year, MedTech’s portfolio of medical technology and healthcare categories included more than 3,900 nominations from more than 15 countries, of which MedTech OptiLight selected for this prestigious honor. This achievement follows awards given by MedTechàLumenis for “Best Comprehensive Medical Device Company 2021” and “Best New Surgical Technology Solution 2020”.

This press release includes multimedia. See the full press release here:

(Graphic: Business Wire)

(Graphic: Business Wire)

OptiLight is a revolutionary light-based treatment. It’s the first and only FDA-approved light therapy for dry eye syndrome, a very common condition that causes dry, sandy eyes and blurred vision in nearly 49 million Americans.1. The innovative and patented Optimal Pulse Technology (OPT™) provides a targeted, uniform, precise and controlled treatment that safely and effectively breaks the vicious cycle of inflammation associated with dry eye syndrome.

“Dry eye syndrome is very common and difficult to treat, and traditional treatments such as warm compresses and artificial tears treat symptoms but do not treat the underlying disease,” said James Johnson, managing director of MedTech Breakthrough. OptiLight is leading a revolution in the management of dry eye syndrome with ‘groundbreaking’ technology that allows clinicians to treat patients quickly and in the office. With great potential for tens of millions of people with dry eye syndrome, OptiLight is poised to become the ‘best new technology solution for ophthalmology of 2022.’

Lumenis introduced OptiLight in May 2021 and recently launched a national advertising campaign featuring singer, songwriter, and actress Mandy Moore (this is us) to raise awareness of dry eye syndrome and encourage people with symptoms to see a doctor who offers OptiLight (

“We are grateful to MedTech for recognizing OptiLight for its innovations and their impact on eye care,” said Tzipi Ozer Armon, CEO of Lumenis. “Lumenis is committed to raising the bar for patients’ health by providing advanced solutions and treatment innovations. As the only light-based treatment for dry eye syndrome, OptiLight has the potential to raise the bar for dry eye control and improve the health and quality of life for millions of people around the world.”

1. Dana R et al. Patient-reported dry eye disease burden in the United States: results of an online cross-sectional survey. I J Eyes. 2020 Aug 216: 7-17.

About Lumenis

Lumenis is a leading manufacturer of energy-based medical devices for cosmetic and ophthalmological applications in the field of minimally invasive clinical solutions. Recognized as a world-renowned expert in the development and commercialization of innovative light-based technologies, including lasers, intense pulsed light (IPL) and radio frequency (RF). For nearly 50 years, Lumenis innovative products have changed treatments and set many high technological and clinical standards. Lumenis creates successful solutions for previously untreated health conditions, as well as advanced technologies that revolutionize current treatment methods.

About MedTech Breakthrough

part ofTech Breakthrough, a market-leading intelligence and recognition platform for innovation and leadership in global technology, The MedTech Breakthrough Awards are dedicated to honoring excellence in medical technology companies, healthcare, products, services and people. MedTech Breakthrough Awards provide a platform for public recognition of corporate achievements and revolutionary medical and healthcare products in categories including customer engagement, mobile health, health and fitness, clinical management, healthcare IoT, medical data, healthcare cybersecurity and much more. Learn more at

PB-00044810 Rev. A

The original text of this announcement is the official approved version. Translations are provided for convenience only and must refer to the text in the original language, which is the only copy of the text with legal effect.


Colin Ketchum

source: work wire

Leave a Comment